Department of Radiotherapy, Eye Ear Nose and Throat Hospital, Shanghai Medical College, Fudan University, PR China.
Department of Radiotherapy, Jiangxi Cancer Hospital of Nanchang University, PR China.
Radiother Oncol. 2022 Aug;173:292-298. doi: 10.1016/j.radonc.2022.06.007. Epub 2022 Jun 16.
To study the prevalence of nodal metastases in sinonasal adenoid cystic carcinoma (SNACC) and to evaluate whether prophylactic neck irradiation (PNI) should be performed in patients with clinical N0 (cN0) disease.
Between April 1992 and November 2020, 166 patients with SNACC who had undergone radiotherapy at our department were retrospectively analyzed. The median follow-up time was 71.3 months.
Among 166 cases of SNACC, a total of 13 (7.8%) had retropharyngeal or cervical nodal metastasis and 93% (12/13) cases occurred in patients with advanced T stage (T3-T4). Levels VIIa, Ib, and IIa were the most common sites of initial nodal involvement. Only 1.2% (2/166) of patients presented late neck recurrence. Lymph node metastasis independently predicted a poor progression-free survival (PFS) (P = 0.017) but had no impact on overall survival (OS) (P = 0.38). PNI was performed on 36% (55/153) of cN0 patients. The OS (P = 0.42), PFS (P = 0.59), nodal recurrence-free survival (NRFS) (P = 0.46) and distant metastasis-free survival (DMFS) (P = 0.63) rates showed no significant difference between cases with and without PNI. Furthermore, cN0 patients with T4b (P = 0.53; P = 0.61), tumor origin from maxillary sinus (P = 0.55; P = 0.53) or nasopharynx involvement (P = 0.56; P = 0.60) showed no extended OS or PFS associated with PNI.
Regardless of the T stage or the site of origin, prophylactic neck irradiation (PNI) for cN0 patients did not provide any benefit on OS and PFS, suggesting that its application on such patients is not warranted unless there is clinical suspicion.
研究鼻窦腺样囊性癌(SNACC)淋巴结转移的发生率,并评估临床 N0(cN0)患者是否应行预防性颈部照射(PNI)。
回顾性分析 1992 年 4 月至 2020 年 11 月在我科接受放疗的 166 例 SNACC 患者的临床资料。中位随访时间为 71.3 个月。
在 166 例 SNACC 中,共有 13 例(7.8%)患者出现咽后或颈部淋巴结转移,93%(12/13)的病例发生在 T 分期较晚(T3-T4)的患者中。VIIa、Ib 和 IIa 水平是最初淋巴结受累的最常见部位。仅有 1.2%(2/166)的患者出现迟发性颈部复发。淋巴结转移独立预测无进展生存期(PFS)较差(P=0.017),但对总生存期(OS)无影响(P=0.38)。36%(55/153)的 cN0 患者行 PNI。OS(P=0.42)、PFS(P=0.59)、无局部区域淋巴结复发生存(NRFS)(P=0.46)和无远处转移生存(DMFS)(P=0.63)率在有无 PNI 的病例之间无显著差异。此外,T4b(P=0.53;P=0.61)、上颌窦起源(P=0.55;P=0.53)或鼻咽部累及(P=0.56;P=0.60)的 cN0 患者行 PNI 与延长 OS 或 PFS 无关。
无论 T 分期或起源部位如何,cN0 患者行预防性颈部照射(PNI)对 OS 和 PFS 均无获益,提示除非有临床怀疑,否则不应对此类患者应用 PNI。